addiction
Is Cannabis a Placebo? – Cannabis | Weed | Marijuana
Published
1 year agoon
By
admin
Is cannabis a placebo? What does that even mean?
A placebo is traditionally a pill that has no active ingredients. Drug researchers will split test subjects into a group that receives the actual substance and another group that gets a placebo, or “sugar pill.”
If the group receiving the real substance does better than the placebo group, the researchers conclude the medicine works.
However, placebos aren’t foolproof. Especially when it comes to psychiatric medicine. Many trials on antidepressants, for example, find placebos work just as well as the medication.
The results are even more impressive if you provide a placebo pill that causes a side effect (an “active” placebo).
Suppose you suffer from depression or anxiety and sign up for a new drug trial. The researchers give you a sugar pill that causes dry mouth as a side effect. You don’t know it’s a placebo, but the objective side effects trick your mind into thinking you’re less depressed or anxious.
Is that what’s going on with cannabis? Is cannabis nothing more than an active placebo?
Breaking Blind
Often in drug trials, a participant will “break blind” by figuring out they’re not on the medicine. Suppose the researcher tells you the side effects are drowsiness, and you never feel drowsy. You may conclude they gave you the placebo.
On the flip side, you may conclude you’re on the real thing if you experience drowsiness. If it’s an antidepressant drug, you may feel less depressed.
Breaking blind is a problem for researchers. In the case of antidepressants, breaking blind modifies expectations. It becomes impossible to determine if the participant resolves their depression through the pharmacology of the drug or their beliefs about the drug.
To get around this, researchers use an “active” placebo. But when participants feel the side effects, they believe they’re on the actual drug. In trials that use active placebos, 78% had no clinical difference in the outcomes.
Most antidepressants work just as well as placebos. So is the same true for cannabis? Is cannabis an active placebo?
It’s true – most psychological and emotional effects of cannabis aren’t actually caused by the pharmacology of the herb.
Let me explain.
Is Cannabis a Placebo?
At Harvard in the late 1960s, two researchers ran a controlled study on the effects of cannabis on people who had never consumed it nor had any experience with it. That included seeing other people use it.
The results were inconsistent without a cultural framework to base the experience around. Two books came from that study. Dr. Andrew Wiel’s The Natural Mind: A Revolutionary Approach to the Drug Problem. And Drug, Set, and Setting: The Basis for Controlled Intoxicant Use by Norman E. Zinberg, M.D.
As Weil wrote,
To my mind, the best term for marijuana is active placebo – that is, a substance whose apparent effects on the mind are actually placebo effects in response to minimal physiological action.
And it’s not just cannabis. According to Weil and Zinberg, any drug providing a high also creates an active placebo in the user’s brain.
This doesn’t deny the pharmacological effects of cannabis. When you consume cannabis, phytocannabinoids activate your cannabinoid receptors. You feel high or stoned.
But everything else is expectation. This isn’t controversial with LSD. “Set and setting” determine whether your trip will be a good one or a bad one.
Likewise, cultural conventions and learned connections influence our thinking on what cannabis does to the mind.
Is Cannabis Really Just a Placebo? No way!
No way cannabis is a placebo. I must be out to lunch. But far from being a bad thing, this is a liberating realization.
For one, it places the onus on the consumer. Yes, cannabis will feel like someone has wrapped a warm blanket around you. If it’s a good strain, you’ll feel the headband. But how you interpret those physical feelings is entirely up to you.
Does cannabis relax you after a hard day’s work, or does it stimulate your creativity like an afternoon coffee? Maybe cannabis makes you feel anxious and paranoid, and you consume it only if you’re in pain.
Does cannabis make you more sensitive? Aroused? Or do you become more withdrawn or numb?
Correlation is Not Causation
I remember once, as a younger man hitchhiking in California. A surfer dude picked me up just south of Monterey. “Wanna smoke a joint?” He asked. “Sure,” I said. So we did. While driving. He became a terrible driver, and I got out soon after.
I couldn’t understand why. Was he faking it? Cannabis makes me concentrated and focused. This guy became distracted and impaired.
I’ve met people who became belligerent after a dab. Others become more agreeable. Some people become bold and talkative, while others become timid and nervous.
But the only thing cannabis is doing is sending phytocannabinoids through your system. Everything else is in your mind.
Consider – have you ever been on a walk or in the shower and thought of an idea? Or maybe a solution to a nagging problem? You weren’t thinking of it. It just popped out of nowhere.
Walking and showering are relaxing. They relieve stress. This influences the endocannabinoid system, and in return, the mind surprises you.
Likewise, when you influence the endocannabinoid system with THC, the mind can become a playground.
Is Cannabis A Placebo?
Is cannabis a placebo? Much depends on what you’re consuming it for, but generally, cannabis (like all drugs) is an active placebo.
That’s not to say cannabis isn’t pain-relieving or helping other physical ailments. The brain and body still process phytocannabinoids, which have a real pharmacological effect.
But does cannabis relieve stress? If you pair cannabis with an intent to relax, the answer is yes.
If you’re at a party and a friend invites you to smoke a sativa joint with him. What is your intent? To experience a THC-upper and become more lively?
Stimulation and relaxation are two different things. How can cannabis do both? Stoners have long known about this dichotomy and answered by referring to sativa vs. indica strains.
But sativa and indica strains of cannabis are relevant to growers only. The bushy, resin-dense plant produces more body buzz than its taller, skinner cousin.
So we interpret this body buzz as relaxing “in-da-couch” and the heady buzz of the sativa strain as a stimulant. But all we’re doing is confirming that cannabis is an active placebo.
And this isn’t a bad thing.
Christmas Without Santa Claus
Do you celebrate Christmas? Over 2 billion people worldwide celebrate the holiday in one form or another. For some reason, in the West, the birth of Christ has morphed into a celebration of a fat man who rides a sleigh of flying reindeer and delivers material goods by breaking and entering.
Well, I suppose we let him in voluntarily. The goof goes down the chimney and only demands milk and cookies for payment.
Odds are, if you’re reading this, you know this is a myth. Santa Claus is not real. But I bet you still get into the festivities of Christmas.
Even non-Christians will celebrate the holiday. Why? Because it’s fun. It’s fun to get into the spirit of Christmas.
Likewise, it’s fun to take drugs that have pharmacological effects. The effects on your mind depend on you. Set and setting. It’s been a psychedelic mantra for years.
But this applies to all drugs. From opioid addicts living on the street to middle-class bourgeois cannabis consumers.
In fact, that’s how we solve the opioid crisis. Not by supplying more drugs but by showing how opioid doesn’t provide the value the addict thinks it does. But that’s a different post for another day.
So I’ll leave it at this: Cannabis is an active placebo. But that’s fine.
You don’t look to the chemical composition of Christmas trees and wrapping paper for answers as to why the holiday season is so magical. You know it’s about your thoughts and how you feel about it.
Likewise, what cannabis can do for you isn’t found in its cannabinoid content (unless you’re looking for purely physical effects). It’s all about set and setting—your expectations.
You may like
-
4 Ways Marijuana Can Help You Have A Better Thanksgiving
-
Can Big Alcohol Help The Cannabis Industry
-
California Appeals Court Rejects Marijuana Grow Permit, Citing Federal Illegality
-
Expert Lighting Tips For Successful Indoor Growing Weed
-
Acne And CBD: Exploring Alternative Dermatological Solutions
-
Can I Gift Marijuana This Holiday Season?
addiction
Can Psychedelics Treat Addiction and Alcoholism?
Published
2 months agoon
September 13, 2024By
admin
Psychedelics, once associated primarily with counterculture and recreational drug use, are now being seriously studied for their therapeutic potential in treating drug addiction and alcoholism. Recent research has shown that substances like psilocybin, LSD, and ayahuasca may have profound benefits for individuals struggling with Alcohol Use Disorder (AUD) and substance use disorders (SUD). These compounds are being reconsidered not only for their ability to induce altered states of consciousness but also for their potential to address addictive behaviors and psychological trauma at the root of addiction.
Psilocybin’s Efficacy in Treating Alcohol Use Disorder
One groundbreaking study, conducted at New York University and Johns Hopkins University, demonstrated the potential of psilocybin in treating Alcohol Use Disorder (AUD). The researchers focused on individuals with severe AUD, administering two doses of psilocybin in conjunction with psychotherapy. The results were notable: participants reported a 50% reduction in heavy drinking days over an eight-month period, with some maintaining abstinence from alcohol even a year later.
The trial followed a double-blind, randomized approach and found that the therapeutic effects of psilocybin were superior to those observed with placebo treatments. Dr. Michael Bogenschutz, a lead researcher in the study, emphasized the importance of the psychedelic experience itself in breaking the cycle of addiction. Psilocybin appears to help patients break through entrenched mental patterns, often revealing deeper emotional connections and realizations that drive more meaningful behavior change.
How Psychedelics Influence the Brain to Combat Addiction
The mechanism behind the efficacy of psychedelics in treating addiction is thought to involve neuroplasticity, or the brain’s ability to reorganize and form new connections. By interacting with serotonin 2A receptors, particularly in the prefrontal cortex and default mode network, psychedelics can enable profound shifts in perception and cognition. These altered states of consciousness allow individuals to confront underlying psychological issues, such as trauma or negative emotional patterns, which are often at the core of addictive behaviors.
Many individuals undergoing psychedelic-assisted therapy report experiencing a “reset” of their mental state, facilitating a more open mindset that helps them engage with therapy in a deeper, more effective way. This contrasts with traditional addiction treatments, such as methadone or buprenorphine, which primarily manage withdrawal symptoms but do not address the psychological components of addiction.
LSD and Its Potential in Addiction Treatment
LSD (lysergic acid diethylamide) has also shown promise in treating addiction, particularly alcoholism. Early studies from the 1950s to the 1970s suggested that LSD might help reduce alcohol dependency, but interest in this line of research waned due to regulatory crackdowns on psychedelic research. However, more recent studies have reignited interest in LSD’s therapeutic potential.
A meta-analysis published in the Journal of Psychopharmacology reviewed data from six trials involving over 500 patients. It concluded that a single high dose of LSD, administered in a therapeutic setting, was associated with a significant reduction in alcohol consumption. The study found that LSD’s psychedelic effects could lead to lasting changes in personality traits, such as openness and emotional resilience, which are crucial for overcoming addiction.
Ayahuasca and Addiction Recovery
Ayahuasca, a traditional Amazonian brew containing DMT (dimethyltryptamine) and MAO inhibitors, has been the focus of recent studies examining its potential to treat addiction. Researchers have found that ayahuasca’s intense psychoactive properties, combined with its ability to facilitate introspection and emotional healing, may help individuals overcome opioid and stimulant addiction. A study published in Frontiers in Pharmacology noted that ayahuasca led to significant improvements in mental health and reductions in addictive behaviors.
Ayahuasca ceremonies, often conducted in a spiritual context, have been shown to promote healing through vivid and sometimes challenging visions. Participants often report gaining insights into the underlying causes of their addiction, leading to long-lasting psychological benefits.
Challenges in Psychedelic-Assisted Therapy
While the results of these studies are promising, the use of psychedelics in treating addiction is not without challenges. For one, the psychedelic experience itself can be unpredictable, and not all patients experience the profound mystical or emotional breakthroughs associated with positive outcomes. The effectiveness of psychedelic-assisted therapy appears to be linked to the quality of the therapeutic environment and the expertise of the facilitators, meaning that careful preparation and integration are key to success.
Moreover, while psychedelics like psilocybin and LSD do not appear to be physically addictive, their use must still be carefully regulated to prevent potential psychological risks, such as hallucinations, anxiety, or psychotic episodes in vulnerable individuals. Current research emphasizes the need for controlled settings where trained therapists can guide patients through their psychedelic experiences.
Ongoing Research and Future Directions
Given the promising early results, psychedelic research is entering a new phase, with larger clinical trials currently underway. The National Institutes of Health (NIH) recently allocated $2.4 million to explore the use of psychedelics in treating methamphetamine addiction, further solidifying the role of psychedelics in addiction therapy. Similarly, ongoing studies are looking into psilocybin’s potential to treat opioid addiction and cocaine dependence, conditions that have been notoriously difficult to treat with conventional methods.
As research progresses, it is likely that psilocybin, LSD, and other psychedelics will become more widely recognized as effective tools for addiction treatment. While more research is needed to fine-tune these therapies and better understand their long-term effects, early indications are that psychedelics could revolutionize addiction and alcoholism treatments in the coming decades.
Conclusion
Psychedelics like psilocybin, LSD, and ayahuasca are emerging as potential breakthrough therapies for treating drug addiction and alcoholism. By promoting neuroplasticity and addressing the psychological roots of addiction, these substances offer an alternative to traditional addiction treatments, which often focus on managing symptoms rather than curing the disease. With ongoing research and increasing clinical trials, psychedelic-assisted therapy may become an essential tool in the fight against substance use disorders, offering hope to millions of people who struggle with addiction, such as alcoholism.
Sources
Johns Hopkins Medicine: Psychedelics in Addiction Treatment
Progress in Neuro-Psychopharmacology and Biological Psychiatry
National Institutes of Health (NIH) Research on Psychedelics
Frontiers in Pharmacology: Ayahuasca for Addiction Recovery
JAMA Otolaryngology – Head & Neck Surgery
Related
addiction
The Evolving Opioid Crisis in Europe: Heroin and Synthetic Threats
Published
2 months agoon
September 12, 2024By
admin
The opioid crisis in Europe is growing in complexity, with heroin continuing to dominate the market while synthetic opioids, such as fentanyl and its analogs, emerge as potent new threats. The 2024 EU Drug Markets Report, released by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol, provides a comprehensive analysis of the heroin and synthetic opioid market, detailing the health risks, evolving trafficking routes, and potential future challenges.
Heroin in Decline? Why Synthetic Opioids Pose a New Threat in Europe
Heroin’s Ongoing Impact in Europe
Heroin remains the most commonly used illicit opioid in Europe, with an estimated 1 million high-risk opioid users. The European heroin market is valued at over €5.2 billion annually, indicating the persistent demand for this drug. In 2021, EU countries seized 9.5 tonnes of heroin, the largest quantity in 20 years. These figures underscore the strong presence of heroin in Europe, despite the introduction of harm reduction programs aimed at curbing opioid use.
The health consequences of heroin use are severe. In 2021, opioids were responsible for three-quarters of Europe’s 6,000 drug-related overdose deaths, with heroin being a leading factor. Long-term users are aging, adding complexity to public health strategies, as older opioid users present with more chronic health problems.
Afghanistan’s Opium Ban: Future Implications for Heroin Supply
Nearly all heroin consumed in Europe is derived from opium produced in Afghanistan. However, Afghanistan’s opium production has seen a dramatic decline following the Taliban’s 2022 ban on poppy cultivation, which led to a 95% reduction in production by 2023. While the immediate impact on heroin availability in Europe has been minimal, the report warns that a sustained ban could lead to future heroin shortages. Such shortages could open the door for synthetic opioids to dominate the market.
The decline in Afghan opium cultivation from 233,000 hectares in 2022 to just 10,800 hectares in 2023 has raised concerns about the future of heroin availability in Europe. Should the Taliban continue to enforce the ban, experts believe the resulting heroin scarcity could increase the use of more potent and dangerous synthetic opioids, exacerbating the public health crisis.
The Rise of Synthetic Opioids: Fentanyl and its Analogues
Synthetic opioids, such as fentanyl, are becoming more prevalent in the European drug market. These substances are far more potent than heroin, and even small doses can lead to fatal overdoses. The 2024 report highlights how these synthetic opioids are contributing to a growing number of overdose deaths and hospital emergencies across Europe. In countries such as Estonia and Sweden, fentanyl is responsible for a significant proportion of drug-related deaths.
Fentanyl analogs are particularly concerning because they can be mixed with other drugs like heroin or cocaine, often without the user’s knowledge. The increasing presence of these synthetic opioids is a major public health concern, as traditional harm reduction measures, such as naloxone distribution and needle exchange programs, are less effective against these more potent substances.
Changing Trafficking Routes and Criminal Networks
Traffickers are increasingly adapting their methods in response to heightened enforcement measures and geopolitical developments. The traditional Balkan route, which brings heroin through Turkey and Bulgaria into Europe, has seen increased enforcement and stricter border controls, prompting traffickers to shift towards alternative routes.
The Southern route is becoming more prominent, with significant heroin shipments passing through Iran and Pakistan before reaching Europe via major seaports. The United Arab Emirates (UAE) has emerged as a key transshipment hub for heroin, providing both logistical support and avenues for money laundering. Meanwhile, the ongoing Russia-Ukraine war has prompted criminal networks to modify their trafficking routes, further complicating law enforcement efforts.
Public Health and Harm Reduction Efforts
Harm reduction strategies have had some success in mitigating the impact of opioid use in Europe. Programs such as opioid substitution therapy (OST) and needle exchange have helped reduce the number of new users injecting heroin, thereby lowering the risks of HIV and hepatitis C transmission. However, the growing prevalence of synthetic opioids poses new challenges. These potent drugs often require stronger overdose prevention measures, such as fentanyl test strips and more widespread access to naloxone, an opioid antagonist used to reverse overdoses.
Additionally, the report notes the importance of expanding data collection and improving early warning systems to monitor emerging trends in opioid use and trafficking. These systems allow public health authorities and law enforcement to respond more quickly to new synthetic opioids entering the market.
Challenges in Treating Opioid Addiction
Treatment for opioid addiction, particularly heroin, is evolving. Europe’s aging population of opioid users presents new challenges, as older users are more likely to have complex medical conditions. Many long-term users require not just drug treatment but also social support and healthcare for chronic conditions related to long-term substance use. Furthermore, gender-specific issues are emerging, as women who use opioids face more barriers to accessing treatment and are more likely to present with co-occurring psychological or social issues.
Conclusion
The opioid crisis in Europe is evolving, with heroin still posing a significant threat to public health, while synthetic opioids like fentanyl are emerging as an even more dangerous force. The reduction in Afghan opium production and the shifting trafficking routes complicate the landscape further. To tackle this complex issue, Europe must continue to invest in harm reduction, international cooperation, and early warning systems to prevent more overdose deaths and manage the changing face of the opioid market. Without a coordinated response, Europe risks facing an even more devastating public health crisis in the coming years.
Related
The fact that some people are eating dogs and cats is a highly sensitive topic that crosses cultural, social, and ethical boundaries. In many regions, these animals are consumed due to cultural traditions and necessity, while in other cases, drug-induced behavior may lead individuals to engage in extreme or unusual dietary practices. This article aims to explore the distinction between cultural norms and the desperate, erratic behaviors driven by substance abuse, focusing on the need for cultural sensitivity while addressing harmful behavior.
When Culture Meets Addiction: Who Is Eating Dogs and Cats?
Cultural Practices and the Consumption of Non-Traditional Animals
In some parts of Asia and Africa, the phenomena of eating dogs and cats has historical roots that are tied to both cultural traditions and the availability of resources. In these regions, the eating of non-traditional animals is a normalized practice and is not connected to drug-fueled behavior.
- Cultural Normalcy: In regions such as South Korea, China, and Vietnam, dogs have historically been consumed as part of traditional cuisines. This practice is not driven by addiction or desperation but by cultural norms that view these animals as a food source rather than pets.
- Food Scarcity: In some communities, especially in impoverished or rural areas, consuming non-traditional animals like dogs or cats is a practical response to food scarcity. The decision to eat these animals is based on survival rather than personal preference or altered judgment.
Drug-Induced Dietary Choices: When Addiction Leads to Extreme Behaviors
In contrast to cultural practices, there are cases where individuals under the influence of drugs engage in extreme or bizarre behaviors, such as eating dogs and cats… This behavior is driven by impaired judgment, psychosis, or desperation caused by addiction, and often occurs in isolated or marginalized communities.
- Methamphetamine and Erratic Behavior: Meth users are known to exhibit extreme and irrational behaviors, including eating animals they wouldn’t normally consider food. Meth-induced psychosis can blur the lines between reality and hallucination, leading to bizarre dietary choices such as consuming pets or strays.
- Desperation from Heroin Addiction: Heroin addicts, especially those living in extreme poverty, may consume non-traditional animals out of necessity. Chronic malnutrition and impaired judgment, combined with isolation from society, can drive addicts to make choices they wouldn’t otherwise consider.
Understanding the Cultural vs. Drug-Fueled Divide
It’s crucial to differentiate between cultural practices and behaviors driven by addiction when discussing the consumption of non-traditional animals. Respecting cultural practices while addressing the harmful impacts of substance abuse requires a nuanced understanding of these different contexts.
- Cultural Sensitivity: When discussing the consumption of non-traditional animals, especially in regions where this practice is accepted, it is important to approach the subject with cultural sensitivity. Condemning these practices without understanding their historical and social context can perpetuate stereotypes and breed intolerance.
- Addressing Addiction-Related Behaviors: Conversely, when the consumption of animals like dogs and cats is tied to addiction, the focus should be on treating the root causes of drug abuse rather than criminalizing individuals. Rehabilitation, mental health support, and access to food resources are critical in preventing desperate behaviors.
Ethical Considerations and Animal Welfare
Regardless of whether the consumption of non-traditional animals is driven by culture or desperation, the ethical treatment of animals is a key concern. The dog and cat meat industries have come under scrutiny for their inhumane treatment of animals, and organizations worldwide are working to promote animal welfare and ethical eating practices.
- Animal Rights in Cultural Contexts: While respecting cultural traditions, animal rights organizations are increasingly advocating for more humane practices within these industries. Campaigns to ban or reduce the consumption of dog and cat meat have gained traction, with a focus on reducing cruelty and promoting alternative food sources.
- Animal Cruelty and Drug Addiction: In cases of drug-induced behaviors, the animals involved often suffer from neglect or harm. Providing support for addicts and ensuring animals are removed from harmful environments can help mitigate this issue.
How to Approach the Issue Globally
Addressing the issue of non-traditional animal consumption, whether cultural or drug-fueled, requires a global approach that balances respect for cultural practices with the promotion of humane treatment for animals. Public health initiatives and cultural sensitivity training can help bridge the gap between different viewpoints while ensuring that animals and people alike are treated with dignity.
- Promoting Cultural Understanding: Efforts to educate the public on the cultural contexts of eating non-traditional animals can help reduce prejudice and promote more respectful global dialogues. Cultural exchange programs and educational campaigns can provide a more nuanced view of these practices.
- Addressing Substance Abuse: On the other hand, combatting the desperation and irrational behavior caused by addiction requires investments in mental health, addiction treatment, and public welfare systems. Providing addicts with support, housing, and access to food can reduce the likelihood of harmful or extreme behaviors.
Conclusion
While the consumption of non-traditional animals like dogs and cats may be culturally accepted in some regions, drug-induced behaviors that lead to similar actions must be understood in a different light. It’s important to address addiction-related behavior with compassion, focusing on rehabilitation and support rather than punishment. At the same time, promoting animal welfare and humane practices in regions where these animals are consumed can create a more ethical global community. By approaching these issues with respect for cultural diversity and a commitment to reducing harm, both animals and humans can benefit.
Related
4 Ways Marijuana Can Help You Have A Better Thanksgiving
Can Big Alcohol Help The Cannabis Industry
California Appeals Court Rejects Marijuana Grow Permit, Citing Federal Illegality
Expert Lighting Tips For Successful Indoor Growing Weed
Acne And CBD: Exploring Alternative Dermatological Solutions
Can I Gift Marijuana This Holiday Season?
The Best Cocktails For An Easy Festive Thanksgiving
420 Vacations: Planning the Perfect Weed Vacation
Can Microdosing Help Manage Holiday Family Anxiety
11 Weed Shows and Movies on Netflix Worth Watching
Distressed Cannabis Business Takeaways – Canna Law Blog™
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
What you Need to Know
Drug Testing for Marijuana – The Joint Blog
NCIA Write About Their Equity Scholarship Program
It has been a wild news week – here’s how CBD and weed can help you relax
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
A new April 20 cannabis contest includes a $40,000 purse
Your Go-To Source for Cannabis Logos and Designs
UArizona launches online cannabis compliance online course
Trending
-
Cannabis News2 years ago
Distressed Cannabis Business Takeaways – Canna Law Blog™
-
One-Hit Wonders2 years ago
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
-
Cannabis 1012 years ago
What you Need to Know
-
drug testing11 months ago
Drug Testing for Marijuana – The Joint Blog
-
Education2 years ago
NCIA Write About Their Equity Scholarship Program
-
Cannabis2 years ago
It has been a wild news week – here’s how CBD and weed can help you relax
-
Marijuana Business Daily2 years ago
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
-
California2 years ago
A new April 20 cannabis contest includes a $40,000 purse